You are here: Home/Meet Our Doctors

Meet Our Doctors

Curriculum Vitae : Sant P. Chawla, M.D., F.R.A.C.P.
Dr. Sant P. Chawla
Dr. Sant P. Chawla is a pioneering physician whose work in sarcoma oncology has brought him several accolades and recognition as one of the world’s foremost experts of sarcomas and sarcoma therapy. Dr. Chawla holds medical licensures in both Texas and California, and he is board certified in Internal Medicine and Medical Oncology. He is also the current Director of Medical Oncology at the UCLA-Santa Monica Hospital, the current Director of Medical Oncology at Orthopaedic Hospital, and the current Director of Medical Oncology at Century City Hospital. Dr. Chawla also heads the Sarcoma Oncology Center in Santa Monica, CA where he leads clinical cancer research efforts and several ground-breaking cancer treatment approvals. A native of the country of India, Dr. Chawla received his medical degree and completed his
residency training in Internal Medicine at the All India Institute of Medical Sciences in New Delhi. From there, he went on to the Auckland Hospital in Auckland, New Zealand to begin his specialty training in medical oncology. He also completed his fellowship in medical oncology in New Zealand, at the Fellow Royal Australasian College of Physicians (F.R.A.C.P.). Recognized for his outstanding academic accomplishments, he was invited to continue his fellowship in oncology at the prestigious M.D. Anderson Cancer Center of the University of Texas. In the last 60 years, M.D. Anderson has built an international reputation of excellence in cancer patient care, research, education, and prevention. M.D. Anderson is the top-ranked cancer hospital in the United States, making numerous and extraordinary research-based contributions that have benefited people everywhere. In this way, M.D. Anderson has established itself as the leader in innovative cancer therapy, and it is here that Dr. Chawla learned and enhanced his own understanding of the disease, preparing him for a pioneering career in the treatment of sarcomas.

As the leading authority in sarcoma oncology, Dr. Chawla has been extensively involved with sarcoma drugs of the past and present, and his expertise will likely serve as a foundation for the development of future treatments as well. To date, he has published or contributed to over 100 research publications dealing with the nature and the treatment of sarcomas. His publications have illuminated several little known aspects of the disease and have gone on to support breakthrough studies and treatments in sarcoma oncology. Dr. Chawla has also led multiple drug approvals for treatments that have led to the improvement of the overall welfare and quality of life of sarcoma patients. Furthermore, he continues to lead several studies in novel and promising sarcoma treatment. Currently, he is involved in the study of Rexin-G, an innovative targeted therapy that utilizes retroviral agents to deliver cell-growth inhibiting components to specific areas of interest. The significance of the specificity of Rexin-G is that it has the potential to effectively stop the growth and spread of certain cancer cells while causing little or no side effects. Experiencing no side-effects is of paramount importance to patients battling the disease with conventional chemotherapy and have been victim to its ill-effects. Understanding this, and hoping to ease the burden of chemotherapeutic drugs, Dr. Chawla has also been revolutionary in developing treatment aimed to reverse adverse effects, like immuno-suppression and nausea, that are common to chemotherapy.

As the current director of the Sarcoma Oncology Center, Dr. Chawla is intimately involved in several research activities; continuing his long-time commitment to discovery and inventive therapy. Some of his main areas of research include preoperative chemotherapy of Osteosarcoma, Ewing’s sarcoma, and soft tissue sarcoma; intra-arterial chemotherapy in sarcoma and gynecologic malignancies; study of oncogenes in sarcoma, melanoma, and gynecologic malignancies; the role of monoclonal antibodies in diagnosis and treatment of metastatic melanoma; the role of GM-CSF in amelioration of chemotherapy induced myelosuppression; and limb salvage surgery in Osteosarcoma, Ewing’s Sarcoma, and gynecologic malignancies. In reference to this last research area, Dr. Chawla was one of the first in the field to contribute compelling work in saving the extremities of young patients, where amputation was previously the only option. His work has undoubtedly served as a tremendous breakthrough for such patients.

Because of his wealth of experience and great understanding of oncology, Dr. Chawla has enjoyed several academic appointments. He has been a teacher and mentor of hundreds of fellows, residents, and students at premiere institutions like the M.D. Anderson Cancer Center, where he was an assistant professor Department of Medicine-Melanoma/Sarcoma/Medical Gynecology/Oncology, and Cedars-Sinai Medical Center where he was a Co-Director of the Comprehensive Cancer Center. Currently, he serves on the clinical faculty at both the University of California, Los Angeles and the University of Southern California, as well as at the John Wayne Cancer Institute. In these positions, he finds great joy in guiding and teaching the next generation of physicians that will continue the advancement of a field that he helped build and continues to lead.


K. Kumar Sankhala, M.D. (Kamalesh Kumar Sankhala, MD)
Kamalesh Kumar Sankhala, M.D. was clinical faculty at University of Texas Health Science Center and Clinical Investigator at Institute for Drug Development (IDD) in San Antonio. He was also a team leader for the Sarcoma program at University of Texas Health Science Center. Prior to joining as faculty in division of oncology and hematology, Dr. Sankhala finished his residency and fellowship from University of Texas Health Science Center and spent two years of additional fellowship in Oncology Drug Development research where he mastered the various facets of development of novel therapeutics at the prestigious Institute for Drug Development (IDD) in San Antonio. Founded by Dr. Daniel Van Hoff, IDD is widely recognized for being the largest Oncology drug development research program in the United States

And has set unprecedented standards for the development of novel anti-cancer agents, playing a pivotal role in the preclinical and clinical development of about 22 new cancer drugs that were subsequently approved by the FDA. Having trained in such an esteemed institute for the development of novel drugs, Dr. Sankhala’s evolution as a physician has led him to translational research of novel anti-cancer agents, studying and evaluating the pre-clinical and clinical implications of these agents in patients with advanced cancers. His clinical expertise includes management of patients with advanced malignancies with novel anticancer drugs as well the optimizing of existing chemotherapeutic agents by reducing toxicities and increasing efficacy, ultimately yielding better responses to chemotherapy. He has an extensive clinical research background, having served as the principal investigator as well as sub-investigator in about 80 Phase-1 clinical trials in addition to sarcoma studies. Dr. Sankhala's clinical practice and research primarily focuses on the adroit management of patients with bone and soft tissue sarcomas, lung cancers in addition to other solid tumors and hematological malignancies. He is the recipient of American Society of Clinical Oncology Foundation Merit Award and AACR-NCI scholarship for Molecular Biology in Clinical Oncology. Dr. Sankhala's prolific work has been published in prestigious journals including Journal of Clinical Oncology, Clinical Cancer Research, Journal of Molecular Cancer Therapy, Current Drug Targets, Expert Opinion in Drug Metabolism Toxicology, Current Drug Targets, Expert opinion on Investigational Drugs and Targeted Oncology. Dr. Sankhala has been a reviewer of reputed Journals in the field of oncology such as British Journal of Cancer, Cancer Chemotherapy & Pharmacology, Journal of Medical Case Report, Onkologie and Bone Marrow Transplantation. He also serves as an editorial board member for Journal of Cancer Science & Therapy and Chemotherapy.

Aside his oncological acumen and accomplishments, Dr. Kamalesh Sankhala also focuses in adult internal medicine stemming from his wide exposure to various illnesses while completing his residency and fellowship in India prior to his time at the University of Texas and Institute for Drug Development. This not only allows him to care for the oncological aspects of a patient with cancer, but provides a comprehensive approach to every patient he cares for.

Doris V. Quon, MD, PhD
Doris V. Quon, MD, PhD is board-certified in Hematology, Oncology and Internal Medicine. She obtained her M.D., Ph.D. at the UCLA School of Medicine and did her Residency in Internal Medicine as well as Fellowship in Hematology-Oncology at Medical Center at UCLA. She first began her training at the Hemophilia Treatment Center at Orthopaedic Hospital in 2000 and is currently the Associate Medical Director at the Center. She has an active roll in coordinating the federally funded (Region IX) Hemophilia activities of the center and is the current Medical Director of the Hemophilia Foundation of Southern California.

  • For more than 75 years, Certification by the American Board of Internal Medicine (ABIM) has stood for the highest standard in internal medicine and its 19 subspecialties and has meant that internists have demonstrated – to their peers and to the public – that they have the clinical judgment....more

  • Ridaforolimus in Treatment of Sarcoma-SUCCEED...more

  • Lazarex Cancer Foundation builds a bridge to hope, dignity and life for cancer patients and their families. We provide financial assistance to defray..more

  • Caris Life Sciences™ Transforming Healthcare Into Human Care..more